Department of Internal Medicine, Division of Hematology and Medical Oncology, Saint Louis University, 3655 Vista Avenu, Saint Louis, MO 63110, USA.
Neurocrit Care. 2011 Aug;15(1):161-5. doi: 10.1007/s12028-009-9320-y.
Heparin-induced thrombocytopenia (HIT)-related cerebral venous sinus thrombosis (CVST) has been described in 10 prior case reports in the English language medical literature. We report the first case of low molecular weight HIT-related CVST with detailed clinical course and novel therapeutic approach.
A 69-year-old woman presented with a focal seizure after total hip replacement. Enoxaparin for venous thromboembolism prophylaxis had been initiated 8 days prior to the seizure.
The patient experienced progressive neurologic deterioration, and MRI and CT angiography were consistent with cerebral sinus thrombosis (CVST). The new onset of thrombocytopenia, thrombosis, and positive heparin ELISA (enzyme-linked immunosorbent assay) and SRA (serotonin release assay) assays confirmed HIT. In spite of aggressive management of HIT-related CVST, including argatroban therapy and endovascular mechanical thrombolysis, the patient expired.
A review of the previous 10 case reports in the literature confirms that HIT-related CVST is often a fatal condition, particularly when diagnosed in comatose patients. Because the diagnosis is rare and often delayed relative to initial presentation, prevention is the key to improve patient outcomes. Newer anticoagulants with different mechanism of action than heparin are currently under review by the FDA; they will facilitate prevention of HIT-related CVST and other HIT-related neurological complications.
在英语医学文献中已有 10 例先前的病例报告描述了肝素诱导的血小板减少症(HIT)相关的脑静脉窦血栓形成(CVST)。我们报告首例低分子肝素诱导的 HIT 相关 CVST 的详细临床过程和新的治疗方法。
一位 69 岁女性在全髋关节置换术后出现局灶性癫痫发作。在癫痫发作前 8 天开始使用依诺肝素进行静脉血栓栓塞预防。
患者出现进行性神经功能恶化,MRI 和 CT 血管造影与脑窦血栓形成(CVST)一致。新出现的血小板减少、血栓形成和阳性肝素 ELISA(酶联免疫吸附试验)和 SRA(血清素释放试验)检测结果证实了 HIT。尽管积极治疗 HIT 相关 CVST,包括阿加曲班治疗和血管内机械溶栓,但患者仍死亡。
对文献中之前的 10 例病例报告的回顾证实,HIT 相关 CVST 通常是一种致命的情况,特别是在昏迷患者中诊断时。由于诊断罕见且通常与初始表现相比延迟,因此预防是改善患者预后的关键。具有不同于肝素作用机制的新型抗凝剂目前正在 FDA 审查中;它们将有助于预防 HIT 相关 CVST 和其他 HIT 相关的神经并发症。